African-American men are more likely to have their prostate cancer return after treatment, but their disease is no more aggressive when it does recur than that of their white counterparts, according to a study led by Duke Prostate Center researchers.
New drugs for multi-drug resistant (MDR) tuberculosis that are expected to shorten the duration of treatment will be available in four to five years time, an expert has said.
Many consumers take precautions against identity theft, but what about medical identity theft? In addition to financial peril, victims can suffer physical danger if false entries in medical records lead to the wrong treatment.
A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
MIT has announced a $100 million gift from Koch Industries executive and MIT alumnus David H. Koch that will usher in new paradigms in highly integrative cancer research. The gift will bring together MIT scientists and engineers under one roof to develop new and powerful ways to detect, diagnose, treat, and manage this often deadly disease.
A UNSW researcher has developed a world-first test which will radically improve cancer management. Professor Philip Hogg, the co-director of UNSW’s Lowy Cancer Research Centre, has developed the technology which will determine whether cancer cells are dying within one day of a patient’s treatment with radiation or chemotherapy.
Rapid assessment and treatment of minor strokes and transient-ischaemic attacks (TIAs) massively reduces the chances of occurrence of subsequent major stroke, conclude two separate studies, one early Online and in an upcoming edition of The Lancet, and the other early Online and in the November issue of The Lancet Neurology.
The study is based on data of patients, treated in any of the 10 Andalusian public hospitals for one year, who were submitted to radiotherapy procedures for the treatment of tumours in the breast, lung, head and neck, cervix and endometrium.
Colorectal cancer (CRC) is currently one of the three most frequent malignancies in Western industrial nations. Although the 5-year survival rate for patients with early stage and local CRC approaches nearly 90%, survival is dramatically decreased by local recurrence and the development of distant metastases that primarily affect the liver, which are the predominant cause of CRC-related mortality.
Pan-European collaboration is important for many clinical trials and essential for trials that are investigating treatments for rare diseases. That was the message delivered today by the European Medical Research Councils (EMRC), the membership organisation for medical research councils across Europe based at the European Science Foundation (ESF) in Strasbourg, which is coordinating two trials in rare diseases and about to launch a review of how best to implement clinical trials that are initiated by investigators.